Published on 21/12/2025
Navigating Global Regulations for Companion Diagnostics
Introduction: The International Landscape of Companion Diagnostics
As precision medicine expands globally, the co-development and approval of companion diagnostics (CDx) has become a critical component of regulatory strategy for both pharmaceutical and diagnostic developers. Companion diagnostics guide the safe and effective use of corresponding drugs, and regulators across the world have established specific frameworks to manage their approval and post-market lifecycle.
This tutorial explores the regulatory expectations across major regions—United States, Europe, Japan, China, Canada, India, and others. Understanding these global frameworks is essential for aligning submission strategies, reducing delays, and achieving concurrent drug-diagnostic approvals.
United States: FDA Regulatory Framework
The U.S. Food and Drug Administration (FDA) regulates companion diagnostics as Class III medical devices. CDx must undergo a Premarket Approval (PMA) process and are reviewed by the Center for Devices and Radiological Health (CDRH) in collaboration with CDER or CBER for the therapeutic product.
- FDA requires CDx to be approved, cleared, or authorized before the associated drug can be marketed.
- Validation data must support both analytical and clinical performance.
- CDx must be referenced in the drug labeling and vice versa.
Key documents:
IDE approval is also necessary for investigational use in pivotal clinical trials.
European Union: EMA and IVDR
In Europe, companion diagnostics are regulated under the In Vitro Diagnostic Regulation (EU IVDR 2017/746), which came into effect in May 2022. Under IVDR, CDx are classified as Class C IVDs and require involvement of a Notified Body and consultation with the European Medicines Agency (EMA).
Key requirements include:
- Performance evaluation (analytical, clinical, and scientific validity)
- EU Declaration of Conformity and CE marking
- EMA consultation for the companion drug
For instance, a CDx co-developed for a targeted cancer therapy must submit both a performance evaluation report and a summary of safety and performance (SSP).
Read EMA diagnostic consultation procedures at EMA.
Japan: PMDA and MHLW
In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) evaluates companion diagnostics, with final approval granted by the Ministry of Health, Labour and Welfare (MHLW). Japan requires simultaneous review of the drug and diagnostic.
- CDx must be filed as “Designated Medical Devices.”
- Consultation with PMDA is mandatory before formal submission.
- Japanese translation and local clinical data are often required.
Timeline optimization in Japan requires strategic pre-submission dialogue, known as “prior assessment consultation.”
China: NMPA/CDx Oversight
China’s National Medical Products Administration (NMPA), formerly CFDA, requires CDx to be approved concurrently with the therapeutic product. NMPA’s regulation is evolving rapidly to align with global norms.
Notable requirements:
- Companion diagnostics must be listed in the drug label.
- Local clinical trials or bridging studies often mandated.
- Product registration classified as Class III for CDx.
NMPA recently emphasized the importance of “coordinated submissions” to support joint approval pathways.
India: CDSCO and Diagnostic Rules
India’s Central Drugs Standard Control Organization (CDSCO) regulates IVDs, including companion diagnostics, under the Medical Devices Rules (2017). CDx are categorized as Class C or D devices and require a detailed registration dossier and Form MD-14 application.
- Local agent or authorized representative is required for foreign manufacturers.
- Clinical performance evaluation may be required unless waived.
- Labeling and shelf-life studies are emphasized by CDSCO.
India also aligns with ISO 13485:2016 and requires local registration for import, as per GSR 102(E).
Detailed application forms and templates are available at PharmaSOP.in.
Canada: Health Canada Guidance
Health Canada regulates CDx under its Medical Devices Regulations. A CDx is considered a Class III device and must be approved before the associated drug is authorized under a Notice of Compliance (NOC).
- Submission requires Device License Application and evidence of effectiveness.
- Simultaneous or staggered drug-diagnostic approvals are possible.
- Companion diagnostics must be referenced in drug labeling.
Post-market requirements include annual license renewal and complaint handling procedures under ISO 13485.
Other Global Regulatory Pathways
Australia (TGA): CDx are classified as Class 3 IVDs, and registration requires conformity assessment certification or recognition under MDSAP (Medical Device Single Audit Program).
Brazil (ANVISA): CDx are regulated as “Type III Risk Devices.” ANVISA requires a Registro application with analytical and clinical performance data, often in Portuguese.
South Korea (MFDS): Companion diagnostics fall under the Medical Device Act and must undergo KFDA evaluation with mandatory Korean translation and local agent representation.
Russia: CDx approval involves the Roszdravnadzor and requires a Clinical Trials of Medical Devices (CTMD) permit. Localization and language compliance are essential.
Common Submission Elements Across Regions
Despite regional variations, most CDx submissions must include:
- Analytical validation (LOD, LOQ, specificity)
- Clinical performance linked to drug efficacy
- Risk classification and intended use
- Manufacturing and quality control data
- Labeling and IFU in local language
Dummy Table: Common Parameters Required
| Parameter | Accepted Range |
|---|---|
| LOD (Limit of Detection) | <0.5 ng/mL |
| Clinical Sensitivity | ≥90% |
| Specificity | ≥95% |
| Reproducibility | Inter-lab CV <10% |
Harmonization Efforts and Industry Best Practices
Regulators and industry groups have launched harmonization initiatives to reduce regulatory duplication and facilitate concurrent approvals:
- International Medical Device Regulators Forum (IMDRF)
- ICH guidelines for diagnostics
- CDRH’s Case for Quality and Total Product Life Cycle (TPLC) programs
Best practices include using global dossier formats, aligning drug and diagnostic development timelines, and planning regulatory consultations early in development.
Visit FDA or ICH for more harmonization resources.
Conclusion
Companion diagnostics operate in a highly regulated global environment. Successfully navigating these frameworks requires a thorough understanding of each country’s unique requirements, strategic planning, and early alignment with therapeutic development. With global harmonization gaining traction, sponsors can increasingly streamline submissions and achieve faster access to markets worldwide—delivering on the promise of personalized healthcare.